NONALCOHOLIC STEATOHEPATITIS (NASH) MODELS
Delivering translatability in NASH studies.
Nonalcoholic steatohepatitis (NASH) is distinguished from other hepatic disorders by hepatocyte ballooning and degeneration as well as lobular inflammation which can eventually deteriorate into liver fibrosis. If it remains untreated, NASH can develop into cirrhosis, and in some instances, hepatocellular carcinoma (HCC).
The biggest challenge in NASH preclinical studies is finding an animal model that provides your pipeline with enough similarity to the human disease state and translatability into clinical applications. Our NASH models at PharmaLegacy offer you with a well-rounded choice that ultimately depends on the facet of NASH your study is tackling. Not sure which model suits you best? Contact our experts at PharmaLegacy who are sure to give you the answers you need.
MODELS / SERVICES
Study Outline
· Male Wistar rats
· Animals were fed an MCD diet for a period of 8 weeks to establish the NASH model
· Animals were treated with vehicle or reference throughout the entire 8-week study
Treatment Groups
Body Weight, Liver Weight
Food intake per rat per day
Serum Levels of ALT (U/L);AST (U/L) and Total Bilirubin(U/L)
H & E Staining (MCD Treated Group)
Sirius Red Staining (MCD Treated Group)
MCD Rat Model Development - Body Weight and Food intake and Relative Liver Weight
MCD Rat Model Development - Serum levels of ALT and AST
MCD Rat Model Development - H&E staining in NASH
STZ-HF Mice Study - Serum Levels of ALT, AST and Glucose
STZ-HF Mice Study - Serum Levels of TC, TG, LDL-C and HDL-C
STZ-HF Mice Study - Histopathology in NASH
STZ-HF Mice Study - Histopathology in NASH
HF-CCl4 Mice Study – Biochemical Data, Liver weight and Hepatic TG
HF-CCl4 Mice Study - Histopathology in NASH
The Capabilities to Succeed:
- Research data electronically managed by BioBook (IDBS, UK)
- Rigorous adherence to international GLP and QA best practices
- FDA part 11 compliant
Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.
We’re ready when you are.
Tell us your pharmacology challenges.
